Crenezumab Misses Primary Target in Alzheimer’s Trial

Crenezumab Misses Primary Targets in Phase II Alzheimer's Trial
Crenezumab Misses Primary Targets in Phase II Alzheimer’s Trial
Reduction in cognitive decline rate not statistically significant compared with placebo group.

The amyloid plaque-busting drug crenezumab for Alzheimer’s disease failed to meet its primary endpoints in a phase II trial, but — as was the case with another similar drug — the drug did show promise in a subgroup with mild symptoms.

Among all patients with mild to moderate Alzheimer’s disease enrolled in the so-called ABBY trial, those assigned to the study drug, a monoclonal antibody called crenezumab, showed a 16.8% reduction in the rate of cognitive decline over 68 weeks compared with a placebo group (P=0.19), reported Jeffrey Cummings, MD, director of the Cleveland Clinic’s Lou Ruvo Center for Brain Health in Las Vegas.

READ FULL ARTICLE Curated publisher From Medical Page Today